Vanguard Group Inc. Raises Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Vanguard Group Inc. grew its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 24.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,803,227 shares of the company's stock after acquiring an additional 755,045 shares during the period. Vanguard Group Inc. owned about 5.57% of EyePoint Pharmaceuticals worth $28,334,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of EYPT. Franklin Resources Inc. grew its holdings in EyePoint Pharmaceuticals by 9.9% during the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock valued at $32,056,000 after purchasing an additional 362,399 shares during the period. Geode Capital Management LLC grew its stake in shares of EyePoint Pharmaceuticals by 16.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company's stock worth $9,583,000 after acquiring an additional 166,699 shares during the period. JPMorgan Chase & Co. increased its holdings in EyePoint Pharmaceuticals by 1,171.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock worth $2,970,000 after acquiring an additional 342,516 shares during the last quarter. Barclays PLC raised its stake in EyePoint Pharmaceuticals by 410.4% in the 3rd quarter. Barclays PLC now owns 245,045 shares of the company's stock valued at $1,959,000 after acquiring an additional 197,033 shares during the period. Finally, abrdn plc purchased a new stake in EyePoint Pharmaceuticals during the fourth quarter valued at about $1,719,000. Hedge funds and other institutional investors own 99.41% of the company's stock.

Analyst Upgrades and Downgrades

EYPT has been the subject of several recent research reports. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a research note on Friday, March 14th. Chardan Capital reiterated a "buy" rating and issued a $33.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Citigroup started coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. Finally, HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, EyePoint Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $26.63.

EyePoint Pharmaceuticals Stock Performance

EYPT traded up $0.13 on Friday, reaching $5.68. The company had a trading volume of 557,917 shares, compared to its average volume of 896,548. EyePoint Pharmaceuticals, Inc. has a 52-week low of $3.91 and a 52-week high of $21.26. The company has a market cap of $390.38 million, a price-to-earnings ratio of -2.84 and a beta of 1.39. The business has a 50 day simple moving average of $5.93 and a 200 day simple moving average of $7.82.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $11.60 million for the quarter, compared to the consensus estimate of $11.02 million. As a group, equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.